Literature DB >> 1701568

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

V J Merluzzi1, K D Hargrave, M Labadia, K Grozinger, M Skoog, J C Wu, C K Shih, K Eckner, S Hattox, J Adams.   

Abstract

A series of dipyridodiazepinones have been shown to be potent inhibitors of human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT). One compound, BI-RG-587, had a Ki of 200 nanomolar for inhibition of HIV-1 RT that was noncompetitive with respect to deoxyguanosine triphosphate. BI-RG-587 was specific for HIV-1 RT, having no effect on feline and simian RT or any mammalian DNA polymerases. BI-RG-587 inhibited HIV-1 replication in vitro as demonstrated by in situ hybridization, inhibition of protein p24 production, and the lack of syncytia formation in cultured human T cell lines and freshly isolated human peripheral blood lymphocytes. Cytotoxicity studies of BI-RG-587 on human cells showed a high therapeutic index (greater than 8000) in culture.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701568     DOI: 10.1126/science.1701568

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  133 in total

1.  A molecular-field-based similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors. 2. The relationship between alignment solutions obtained from conformationally rigid and flexible matching.

Authors:  J Mestres; D C Rohrer; G M Maggiora
Journal:  J Comput Aided Mol Des       Date:  2000-01       Impact factor: 3.686

2.  A molecular-field-based similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  J Mestres; D C Rohrer; G M Maggiora
Journal:  J Comput Aided Mol Des       Date:  1999-01       Impact factor: 3.686

3.  Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases.

Authors:  Iris Oz; Orna Avidan; Amnon Hizi
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

4.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

Review 5.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

6.  Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.

Authors:  Dongyuan Piao; Aravind Basavapathruni; Pinar Iyidogan; Guangxiu Dai; Wolfgang Hinz; Adrian S Ray; Eisuke Murakami; Joy Y Feng; Fei You; Ginger E Dutschman; David J Austin; Kathlyn A Parker; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2012-12-20       Impact factor: 2.823

7.  Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans.

Authors:  J N Gnabre; J N Brady; D J Clanton; Y Ito; J Dittmer; R B Bates; R C Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

Authors:  J Balzarini; A Karlsson; A M Vandamme; M J Pérez-Pérez; H Zhang; L Vrang; B Oberg; K Bäckbro; T Unge; A San-Félix
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

10.  A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.

Authors:  T J Dueweke; T Pushkarskaya; S M Poppe; S M Swaney; J Q Zhao; I S Chen; M Stevenson; W G Tarpley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.